Emerging technologies bring the fight directly to the cancer cells
A major breakthrough in cancer drug delivery took place in 1995, when the FDA approved the first nanodrug, Doxil—a liposomal formulation of doxorubicin engineered to preferentially accumulate in tumors. Since then, the agency has cleared dozens of additional nanoparticle-based cancer therapies.¹ A complementary milestone followed in 2000 with the approval of the first antibody-drug conjugate (ADC), Mylotarg, which used an anti-CD33 antibody to deliver a cytotoxic agent directly to leukemia cells.
These advances have laid the groundwork for a new generation of cancer delivery platforms. What innovations will define the landscape in 2026? To find out, we spoke with four leading companies whose solutions include novel catheter systems, nanotechnologies, and click chemistry approaches.
Read the full article on Read the full article on Genetic Engineering & Biotechnology News